Mondias Announces New Chief Financial Officer

Establishing an Experienced Management Team for Growth

MONTREAL, February 18th, 2020 /CNW/ – Mondias Natural Products Inc. (TSXV: NHP) (the “Company” or “Mondias”) specializing in evidence-based natural products for the healthcare and bio-agriculture markets today announces that Mr. Mario Paradis CPA, CA, ICD.D has joined the Company as Chief Financial Officer (CFO).  Prior to joining Mondias, Mr. Paradis has held CFO roles in consumer healthcare companies such as Atrium Innovations, Acasti Pharma, and Neptune Wellness Solutions.  

Mondias CEO Dr. Patrick Frankham stated that “Mario is a great addition to our growing organisation. Mr. Paradis brings with him an extensive background in corporate finance, mergers and acquisitions, treasury, financial planning and analysis, tax, investor relations, strategic planning and risk management with a deep appreciation for Mondias and its unique position driving natural products for healthcare, agriculture, and functional beverages markets.  Dr. Frankham also added, “I wish to thank Mr. Sabino Di Paola for supporting Mondias through the initial offering stage and wish him luck in his business pursuits.”   

Mr. Paradis was until November 2019, Vice President and Chief Financial Officer at Neptune Wellness Solutions where he participated in the transition from consumer healthcare products to cannabis.  Prior to that, he was Vice President and Chief Financial Officer at Atrium, which was acquired in 2014 by corporations backed by Permira funds in a transaction valued at over $1.1 billion. He was also at Aeterna Zentaris, most notably as Vice President Finance and Administration & Corporate Secretary. Mr. Paradis began his career at PricewaterhouseCoopers (PwC), where he successfully held senior positions primarily in audit and tax.  

Mr. Paradis is a member of the Canadian Chartered Professional Accountants (CPA). He holds a Bachelor degree in Business, with a specialty in Accounting, from Université du Québec à Trois-Rivières.

About Mondias Natural Products Inc.

Mondias specializes in the commercialization and development of evidence-based botanical products for the healthcare, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.

For more information, visit: www.mondias.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by the use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include the Company’s inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company’s research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise except as required by applicable securities legislation.

For more information:
Mondias Natural Products Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
514-943-1899
pfrankham@mondias.ca

Relations Publiques Paradox Inc.
514-341-0408